SECAUCUS, N.J., Feb. 16, 2021 /PRNewswire/ -- Quest
Diagnostics Incorporated (NYSE: DGX), the world's leading provider
of diagnostic information services, announced that it is scheduled
to speak at Citi's 2021 Healthcare Services, Medtech, Tools, &
HCIT Virtual Conference. Mark
Guinan, Executive Vice President & CFO will discuss the
company's vision, goals, and capital deployment strategies.
The presentation is scheduled for Wednesday,
February 24, 2021 at 1:30 p.m.
Eastern Time.
The presentation will be webcast live during the conference and
will be available on the company's investor relations page which
can be accessed at ir.QuestDiagnostics.com. In addition, the
archived webcast will be available within 48 hours after the
conclusion of the live event and will remain available until
March 26, 2021.
About Quest Diagnostics
Quest Diagnostics empowers
people to take action to improve health outcomes. Derived from the
world's largest database of clinical lab results, our diagnostic
insights reveal new avenues to identify and treat disease, inspire
healthy behaviors and improve health care management. Quest
Diagnostics annually serves one in three adult Americans and half
the physicians and hospitals in the
United States, and our nearly 50,000 employees understand
that, in the right hands and with the right context, our diagnostic
insights can inspire actions that transform lives.
www.QuestDiagnostics.com.
About COVID-19 testing at Quest Diagnostics
Quest
Diagnostics is at the forefront of the response to the COVID-19
pandemic, working to broaden access to laboratory insights to help
us all lead healthier lives. We provide both molecular diagnostic
and antibody serology tests to aid in the diagnosis of COVID-19 and
immune response. Our COVID-19 test services are based
on tests that have received FDA emergency use authorization and
which also meet our high standards for quality. We are providing
these test services under the Public Readiness and Emergency
Preparedness Act.
We provide data on COVID-19 testing to various federal and state
public health authorities, including the Centers for Disease
Control and Prevention, and participate in studies with government
and private institutions, aiding COVID-19 public health response
and research. Through our team of dedicated phlebotomists, air
fleet team, couriers and laboratory professionals, Quest
Diagnostics works hard every day to help patients and communities
across the United States access quality COVID-19
testing.
The antibody tests and the molecular tests (together "All
tests") have not been FDA cleared or approved; All tests have been
authorized by FDA under EUAs for use by authorized laboratories;
The antibody tests have been authorized only for the detection of
IgG antibodies against SARS-CoV-2, not for any other viruses or
pathogens; The molecular tests have been authorized only for the
detection of nucleic acid from SARSCoV-2, not for any other viruses
or pathogens; and, All tests are only authorized for the duration
of the declaration that circumstances exist justifying the
authorization of emergency use of in vitro diagnostics for
detection and/or diagnosis of COVID-19 under Section 564(b)(1) of
the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is
terminated or revoked sooner.
For more information about the latest developments with our
COVID-19 testing, visit:
newsroom.questdiagnostics.com/COVIDTestingUpdates
View original content to download
multimedia:http://www.prnewswire.com/news-releases/quest-diagnostics-to-speak-at-citis-2021-healthcare-services-medtech-tools--hcit-virtual-conference-301229173.html
SOURCE Quest Diagnostics